[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

UnitedHealth Group (UNH) – Form 4 insider transaction.

CEO and Director Stephen J. Hemsley reported the acquisition of 198 deferred stock units on 07/01/2025 as part of his regular quarterly board compensation. These units are immediately vested but must be held until he leaves the Board, and the filing shows $0 purchase price (non-cash grant).

Following the award, Hemsley’s beneficial ownership stands at:

• 374,605.942 shares held directly
• 349.7176 shares held through the company 401(k)
• 735,115 shares held via family trusts

No derivative securities were reported, and there were no sales or open-market purchases. The filing appears to be routine compensation-related and does not indicate any change in strategic outlook or financial performance for UnitedHealth Group.

Insights

Securities Analyst

TL;DR: Routine director compensation grant; immaterial size, neutral signal.

The 198-unit deferred stock grant to CEO/Director Stephen Hemsley is a standard quarterly award that vests immediately but is locked up until board service ends. With existing direct and indirect ownership exceeding 1.1 million shares, this grant is de-minimis (<0.02 % of his holdings) and involves no cash outlay. It neither changes insider sentiment nor alters the company’s share supply. For investors, the filing is non-impactful and should not influence valuation or trading decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		S(1)		4,503	D	$11.6321(2)	21,279	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.31 to $11.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Jonathan Allan, Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Stephen J. Hemsley acquire on 07/01/2025?

198 deferred stock units were granted as part of regular board compensation.

What is Stephen J. Hemsley’s total direct ownership in UNH after the transaction?

He now holds 374,605.942 shares directly.

Were any UnitedHealth Group shares sold in this Form 4 filing?

No. The filing reports only an acquisition; no sales occurred.

Does the Form 4 indicate open-market purchases by the CEO?

No. The units were a non-cash, board compensation grant with a $0 price.

How many shares does Hemsley hold indirectly through trusts and the 401(k)?

He holds 735,115 shares via trusts and 349.7176 shares in the 401(k).